'Domestic Market Saturation' Drives K-Botox to Scale Up in Emerging Markets

Domestic Supply Price Drops to Just Above 10,000 Won
Fierce Price War Intensifies
Export Volumes Increase in Central and South America, Middle East
Huons and Chong Kun Dang Pursue Product Approval in China

Domestic botulinum toxin (Botox) companies are turning their attention to emerging markets such as Central and South America to avoid saturation in the domestic market. While intensified price competition in Korea has made it difficult to secure profitability, these companies believe there is significant growth potential overseas due to increasing demand for cosmetic and plastic surgery procedures.

According to global market research firm Precedence Research on February 2, 2026, the global botulinum toxin market, which was valued at $7.21 billion (approximately 9.4 trillion won) in 2022, is projected to expand to $17.98 billion (approximately 23.6 trillion won) by 2032, growing at an average annual rate of 9.6%. The expansion of cosmetic and plastic surgery demand, as well as the increasing number of male consumers, are cited as key drivers of market growth.

The trend of expanding exports among Korean companies is also clear. According to the Korea Health Industry Development Institute's "2026 Pharmaceutical Export Outlook by Product," exports of toxin and toxoid products, including botulinum toxin, reached $419 million (about 608.4 billion won) last year, an increase of 16.6% compared to the previous year. This year, exports are expected to reach $457 million (about 663.6 billion won), up 9.2% from last year.

The shift of the K-Botox industry toward overseas markets is rooted in changes in the domestic market environment. Although botulinum toxin is classified as a high-margin product due to its low manufacturing costs, the entry of numerous latecomers into the Korean market has intensified price competition. According to industry sources, the supply price to domestic hospitals and clinics for a 100-unit vial has dropped from the previous range of 40,000-50,000 won to just over 10,000 won recently.

The performance of the top three domestic toxin companies also reflects this trend. Hugel's cumulative domestic sales of botulinum toxin and fillers in the third quarter of last year were 70 billion won, down about 15% year-on-year. Although this figure includes fillers, the decrease in sales proportion indicates the contraction of the domestic market. For Daewoong Pharmaceutical's Nabota, overseas sales accounted for about 85% of the cumulative sales of 171 billion won in the third quarter of last year.

The industry is paying particular attention to the rapid growth rates in emerging markets such as Central and South America. Unlike the fiercely competitive established markets, companies can increase volume relatively quickly in emerging countries by securing local partners. Especially as cosmetic and plastic surgery procedures are just beginning to become mainstream in these regions, companies expect to benefit from early market entry.

Among emerging markets, China is attracting the most attention. Unlike Korea, China has only seven companies authorized to sell botulinum toxin, so market entry is expected to have a significant impact. Currently, Hugel is the only Korean company to have entered the Chinese market.

Other latecomers are also making moves. On January 9, Huons Biopharma announced that its Chinese partner, iMaker Technology, had received product approval for the botulinum toxin formulation "Hutox" from the National Medical Products Administration (NMPA) of China. This makes Huons Biopharma the second Korean company, after Hugel, to enter the Chinese market. Chong Kun Dang Bio also demonstrated non-inferiority to "Botox" in a phase 3 clinical trial of its botulinum toxin in China, and plans to apply for product approval in China based on these results.

Companies are also accelerating their efforts to target the Central and South American and Middle Eastern markets. Daewoong Pharmaceutical recently signed an export contract with Mexico and is expanding into Central and South American markets such as Brazil and Argentina. In Brazil, the largest market in the region, the company signed a Nabota supply contract worth about 180 billion won. Hugel, after entering Kuwait in 2023, received approval in the United Arab Emirates (UAE) last year and officially entered the market in May of the same year, strengthening its presence in the Middle East.

An industry official explained, "Existing Botox companies have reached their limits in growing through low-price competition in Korea. The trend is now to target the global market from a long-term perspective."

This content was produced with the assistance of AI translation services.